Format

Send to

Choose Destination
Expert Opin Ther Pat. 2015 May;25(5):619-24. doi: 10.1517/13543776.2015.1007954. Epub 2015 Jan 29.

Fibronectin-based scaffold domain proteins that bind myostatin: a patent evaluation of WO2014043344.

Author information

1
University of Cincinnati, College of Medicine, Department of Molecular Genetics, Biochemistry and Microbiology , Cincinnati, OH, 45267 , USA.

Abstract

Muscular dystrophies (MD) are commonly characterized by progressive loss of muscle mass and function. It is hypothesized that therapeutic blockade of the TGF-β ligand myostatin, a negative regulator of muscle mass, will stimulate muscle growth and restore muscle function. Although many anti-myostatin targets are currently being pursued in the clinical setting, the efficacies of the tested molecules have shown mixed results. The patent WO2014043344 describes a novel approach for myostatin inhibition using a modified fibronectin type III domain that could potentially be used to treat MD and other muscle-related pathologies.

KEYWORDS:

TGF-β; biological therapies; fibronectin; growth and differentiation factor-8; muscle wasting; muscular dystrophy; myostatin

PMID:
25632990
DOI:
10.1517/13543776.2015.1007954
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center